[Use and misuse of benzodiazepines in patients with psychiatric disorders]

Presse Med. 2018 Oct;47(10):886-891. doi: 10.1016/j.lpm.2018.10.003. Epub 2018 Oct 25.
[Article in French]

Abstract

The psychiatric patients are not only particularly exposed to benzodiazepines; they may also be more vulnerable to their side effects than general population. Benzodiazepines are frequently misused in psychiatric patients in terms of duration, dose and number of concomitant medications. There is no evidence that benzodiazepines are effective against most psychiatric disorders, including depression and suicidal risk. Several studies have shown associations between benzodiazepine use and depression worsening, increased disinhibition, suicide risk, anxiety, aggression, and even mortality in patients with psychiatric disorders. Despite the common use of benzodiazepine drugs by clinicians, large and methodologically sound studies are lacking to document the patterns of benzodiazepine use in populations with psychiatric disorders and their specific risks in these patients. It is not known whether it is legitimate to apply the good practice recommendations for benzodiazepines in patients with severe psychiatric disorders.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Aggression / drug effects
  • Anxiety Disorders / chemically induced
  • Anxiety Disorders / drug therapy
  • Anxiety Disorders / psychology
  • Benzodiazepines / adverse effects*
  • Benzodiazepines / therapeutic use*
  • Depressive Disorder / chemically induced
  • Depressive Disorder / drug therapy
  • Depressive Disorder / psychology
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Drug Utilization / statistics & numerical data
  • Female
  • Humans
  • Inhibition, Psychological
  • Long-Term Care
  • Male
  • Mental Disorders / drug therapy*
  • Mental Disorders / epidemiology
  • Mental Disorders / psychology
  • Middle Aged
  • Psychotropic Drugs / adverse effects
  • Psychotropic Drugs / therapeutic use
  • Risk Assessment
  • Suicidal Ideation

Substances

  • Psychotropic Drugs
  • Benzodiazepines